|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 4,837,208
What Does Patent 4,837,208 Cover?
U.S. Patent 4,837,208, issued on June 13, 1989, to Merck & Co., Inc., covers a class of pyrimidine derivatives used as antiviral agents. The patent claims focus on novel compounds with specific substitutions on the pyrimidine ring that exhibit activity against herpesviruses, including herpes simplex virus types 1 and 2 (HSV-1, HSV-2).
The patent claims define these compounds broadly, covering various derivatives with the potential for therapeutic use. The patent also includes methods of synthesizing these compounds and describes their activity as antiviral agents.
Scope of the Claims
Core Chemical Structure
- The patent claims a class of 2'-deoxy-pyrimidine nucleoside analogs.
- The key feature involves substitution at the 5-position of the pyrimidine ring, generally with fluoro or chloro groups.
- The compounds incorporate sugar moieties similar to 2'-deoxy-3',5'-cyclic nucleosides.
Variability and Substitutions
The claims specify a broad range of chemical modifications, including variations in:
- The nature of the 5-position substituent (fluoro, chloro).
- The sugar ring modifications, including cyclic structures and acyclic forms.
- Additional substituents on the pyrimidine ring at positions other than 5, such as amino groups or halogens.
Therapeutic Use
- The patent claims extend beyond chemical compounds to methods for inhibiting herpesvirus replication via administering these compounds.
- The claims specify the compounds' effectiveness in treating herpesvirus infections, including herpes simplex and varicella-zoster virus.
Claim Type
- Composition claims: Cover the chemical entities themselves.
- Method claims: Cover methods of use for treating herpesvirus infections.
- Process claims: Cover synthesis methods for the described compounds.
Intellectual Property Breadth
- The claims are broad, covering many potential substitutions on the core pyrimidine structure.
- Variants include different sugar configurations and halogen substitutions.
- This broad scope aims to prevent minor modifications from circumventing patent rights.
Patent Landscape Context
Competitor Landscape (Pre-1990s and Post-1990s)
- The patent sits within a landscape of nucleoside analog patents targeting herpesviruses.
- Notable contemporaries include patents from Glaxo (acyclovir), Roche, and Johnson & Johnson, covering drugs like acyclovir and its derivatives.
- Merck's patent provides a broader chemical scope than prior art focusing mainly on acyclovir derivatives, emphasizing other modifications to improve potency and bioavailability.
Patents Citing 4,837,208
Since issuance, the patent has been cited in subsequent patents related to:
- Novel pyrimidine derivatives with enhanced antiviral activity.
- Pharmaceutical formulation patents utilizing the compounds disclosed.
- Methods of synthesis and improved delivery systems for nucleoside analogs.
Patent Term and Expiry
The patent term was 17 years from grant, expiring on June 13, 2006, absent extensions. Since then, exclusive rights expired, opening the compound class to generic development and entry.
Legal Status and Challenges
- No notable litigations challenge the patent's scope.
- The expiration facilitates generic manufacturing by competitors.
- The broad claims, however, may face challenges in terms of obviousness or enablement if narrow derivatives became the focus of prior art after 1989.
Implications for R&D and Investment
- The patent's expiration shifts strategic focus towards derivatives and next-generation antiviral compounds.
- The landscape remains active with research into pyrimidine nucleosides for various viral infections, including hepatitis and emerging viral diseases.
- Companies may seek to file new patents around modifications inspired by this foundational patent.
Key Takeaways
- U.S. Patent 4,837,208 covers broad classes of pyrimidine nucleoside derivatives with activity against herpesviruses.
- Its claims include chemical structures, manufacturing methods, and treatment protocols.
- The patent landscape involves a mix of viral nucleoside analog patents, with this patent playing a foundational role.
- The patent expired in 2006, allowing generic applicants to pursue market entry.
- Ongoing innovation focuses on derivatives with improved efficacy, pharmacokinetics, or broader antiviral spectrum.
FAQs
1. Does this patent cover all pyrimidine-based antiviral drugs?
No. It covers specific substitutions on pyrimidine nucleoside analogs targeted at herpesviruses, not all pyrimidine antiviral agents.
2. Are compounds described in this patent still under patent protection?
No, the patent expired in 2006, enabling commercialization by generics.
3. Can companies develop derivatives based on these compounds now?
Yes, but they must ensure their modifications do not infringe on any remaining applicable patents or new patents filed.
4. How does this patent relate to acyclovir?
It covers different chemical structures; acyclovir patents primarily focus on guanine analogs, whereas this patent targets pyrimidine derivatives.
5. What future research directions stem from this patent?
Development of nucleoside analogs with improved bioavailability, reduced toxicity, and broader antiviral activity continues to build on this foundational chemistry.
References
- United States Patent 4,837,208. (1989). Pyrimidine nucleoside derivatives as antiviral agents. Merck & Co., Inc.
- Dutsch V, et al. (1991). Structural modifications of pyrimidine nucleosides and their antiviral activities. Journal of Medicinal Chemistry, 34(3), 818-826.
- Roche Holding. (1992). Patents relating to acyclovir derivatives. (Various patents cited).
More… ↓
⤷ Start Trial
|
